Oral treatment for acquired angioedema due to C1 inhibitor deficiency
Treatments studied
Part of Genetic & congenital, Heart & circulation, Immune system & allergy, Skin clinical trials.
This study tests an oral medication that can be taken daily to prevent angioedema attacks and as a rescue treatment when attacks occur. It may help reduce the frequency and severity of swelling episodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults aged 18 years or older
- Diagnosis of acquired angioedema due to C1 inhibitor deficiency
- History of angioedema attacks before the start of the study
- Ability to use an electronic device to record symptoms and attack information
- Not currently satisfied with long-term preventive treatment for angioedema
- Not pregnant, planning to become pregnant, or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication (sebetralstat) for treating angioedema attacks in children aged 2 to 11 with hereditary angioedema (HAE). The goal is to see if this medicine can safely relieve swelling and pain during an attack, offering a convenient at-home treatment option for kids.
This study tests a new medicine, donidalorsen, to prevent swelling attacks in children ages 2 to 11 with hereditary angioedema (HAE). If your child has HAE type 1 or 2, this trial may help find a treatment option.
This study tests a daily oral tablet called deucrictibant to see if it can prevent swelling attacks in people with hereditary angioedema (HAE). If you join, you will take the study drug for a longer period and track your symptoms in a diary.
This trial tests an oral medication called deucrictibant to prevent and treat swelling attacks in people with hereditary angioedema. It may help reduce the number and severity of attacks.
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
This expanded access program offers an investigational medication called deucrictibant immediate-release to people with hereditary angioedema (HAE) who have no good treatment options for their acute attacks. It aims to provide relief when other approved therapies haven't worked or aren't suitable.
Hear when a new Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.